Activated Protein C for Severe Sepsis
- 26 September 2002
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (13) , 1035-1036
- https://doi.org/10.1056/nejm200209263471315
Abstract
In this issue of the Journal, Warren et al.1 and Siegel2 offer their views on the approval of drotrecogin alfa (activated), or recombinant human activated protein C, for the treatment of severe sepsis. We concur with Dr. Siegel's comments regarding the extensive testing to ensure the potency and consistency of drotrecogin alfa (activated) used in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.3 It is fortunate that the master cell bank used to produce the drug administered in the latter portion of the trial will be sufficient to meet clinical needs for several decades.Keywords
This publication has 3 references indexed in Scilit:
- Assessing the Use of Activated Protein C in the Treatment of Severe SepsisNew England Journal of Medicine, 2002
- Risks and Benefits of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001